Amgen (AMGN): Good AMG334 Migraine Results, But Not Differentiated - Leerink

Leerink Partners, Geoffrey Porges, reiterated his Market Perform rating on shares of Amgen (NASDAQ: AMGN) after Amgen revealed the secondary endpoints of its phase 2 chronic migraine trial for erenumab this week at the European Headache and Migraine Trust International Congress in Glasgow.

The study met its key secondary endpoint, the proportion of patients experiencing at least a 50% reduction in migraine days, with both dose cohorts (70mg and 140mg monthly SC) achieving statistical significance vs. placebo (40% and 41%, respectively, vs. 24%). These values, however, failed to differentiate erenumab from competing programs from Alder (NASDAQ: ALDR) and Teva (NYSE: TEVA) – although the results continue to validate the class of CGRP targets for the treatment of migraines.

For an analyst ratings summary and ratings history on Amgen click here. For more ratings news on Amgen click here.

Shares of Amgen closed at $172.64 yesterday.

You May Also Be Interested In

• Temenos AG (TEMN:SW) (TMSNY) PT Lowered to CHF65 at Citi
• CONMED (CNMD) PT Lowered to $107 at Needham
• Donnelley Financial Solutions (DFIN) PT Raised to $72 at B.Riley